Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGIAVINA-BIANCHI, Pedro
dc.contributor.authorGALVAO, Violeta Regnier
dc.contributor.authorPICARD, Matthieu
dc.contributor.authorCAIADO, Joana
dc.contributor.authorCASTELLS, Mariana C.
dc.date.accessioned2017-08-17T19:14:50Z
dc.date.available2017-08-17T19:14:50Z
dc.date.issued2017
dc.description.abstractBACKGROUND: Rapid drug desensitization (RDD) has become a cornerstone in the management of immediate drug hypersensitivity reactions (DHRs) to chemotherapeutic agents. Because of the inherent risk of anaphylaxis during RDD, biomarkers to predict patients at risk of developing such severe reactions are needed. The basophil activation test (BAT) has been used in DHRs as a diagnostic tool. OBJECTIVE: We evaluated basophil CD63 and CD203c expression (BAT) as a biomarker to assess the safety and effectiveness of RDD in platinum compounds-allergic patients. METHODS: Patients allergic to platinum compounds (n = 15) undergoing RDD were assessed through clinical history, skin testing, serum tryptase levels, and BAT. BAT was performed immediately before RDD, assessing CD203c and CD63 expression on basophils. BAT was also performed in 6 patients tolerant to platinum compounds and in 6 healthy volunteers. RESULTS: BAT was positive to CD203c or CD63 in 11 out of 15 patients allergic to platinum compounds (73%), with increased expression of CD203c and CD63 in 11 (73%) and 6 (40%) patients, respectively. Increased CD63 expression tended to be associated with more severe initial reactions. All controls had negative test results. Reactions during RDD were associated with BAT positivity and increased tryptase levels. Only 1 of 4 patients with negative BAT had a mild reaction during RDD. BAT remained positive in multiple sequential RDD. CONCLUSIONS: BAT identified patients allergic to platinum compounds with an increased risk of reactions during desensitization and higher CD63 expression was observed in severe reactions. Multiple RDDs to platinum compounds did not induce persistent hyporesponsiveness on basophils. BAT is a potential biomarker for RDD. (C) 2016 American Academy of Allergy, Asthma & Immunology
dc.description.indexMEDLINE
dc.description.sponsorshipAlgorithme Pharma
dc.description.sponsorshipSanofi
dc.description.sponsorshipMerck
dc.description.sponsorshipNational Institutes of Health
dc.identifier.citationJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, v.5, n.3, p.728-736, 2017
dc.identifier.doi10.1016/j.jaip.2016.11.006
dc.identifier.eissn2213-2201
dc.identifier.issn2213-2198
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21224
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofJournal of Allergy and Clinical Immunology-In Practice
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE BV
dc.subjectAnaphylaxis
dc.subjectBasophil activation test
dc.subjectDrug allergy
dc.subjectPlatinum compounds
dc.subjectRapid drug desensitization
dc.subject.otherfc-epsilon-ri
dc.subject.otherhypersensitivity reactions
dc.subject.othermonoclonal-antibodies
dc.subject.otherclinical-features
dc.subject.othercolorectal-cancer
dc.subject.othercd63 expression
dc.subject.otherovarian-cancer
dc.subject.otherup-regulation
dc.subject.othercows milk
dc.subject.othercarboplatin
dc.subject.wosAllergy
dc.subject.wosImmunology
dc.titleBasophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisopt
hcfmusp.affiliation.countryisous
hcfmusp.author.externalPICARD, Matthieu:Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA; Univ Montreal, Dept Med, Div Allergy & Immunol, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
hcfmusp.author.externalCAIADO, Joana:Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA; Hosp Santa Maria, Ctr Hosp Lisboa Norte, Immunoallergol Dept, Lisbon, Portugal
hcfmusp.author.externalCASTELLS, Mariana C.:Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA
hcfmusp.citation.scopus72
hcfmusp.contributor.author-fmusphcPEDRO FRANCISCO GIAVINA-BIANCHI JUNIOR
hcfmusp.contributor.author-fmusphcVIOLETA REGNIER GALVAO
hcfmusp.description.beginpage728
hcfmusp.description.endpage736
hcfmusp.description.issue3
hcfmusp.description.volume5
hcfmusp.origemWOS
hcfmusp.origem.pubmed28034549
hcfmusp.origem.scopus2-s2.0-85009224879
hcfmusp.origem.wosWOS:000405923700025
hcfmusp.publisher.cityAMSTERDAM
hcfmusp.publisher.countryNETHERLANDS
hcfmusp.relation.referenceAkdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754
hcfmusp.relation.referenceAndrews NL, 2009, IMMUNITY, V31, P469, DOI 10.1016/j.immuni.2009.06.026
hcfmusp.relation.referenceBalzer L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108619
hcfmusp.relation.referenceBidad K, 2014, CYTOM PART B-CLIN CY, V86, P183, DOI 10.1002/cyto.b.21148
hcfmusp.relation.referenceBrennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009
hcfmusp.relation.referenceBrown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029
hcfmusp.relation.referenceCaiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002
hcfmusp.relation.referenceCastells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044
hcfmusp.relation.referenceCernadas JR, 2010, ALLERGY, V65, P1357, DOI 10.1111/j.1398-9995.2010.02441.x
hcfmusp.relation.referenceCox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060
hcfmusp.relation.referencede Weck AL, 2008, INT ARCH ALLERGY IMM, V146, P177, DOI 10.1159/000115885
hcfmusp.relation.referenceFord LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003
hcfmusp.relation.referenceGadducci A, 2008, INT J GYNECOL CANCER, V18, P615, DOI 10.1111/j.1525-1438.2007.01063.x
hcfmusp.relation.referenceGiavina-Bianchi P, 2013, ALLERGY, V68, P1482, DOI 10.1111/all.12228
hcfmusp.relation.referenceGiavina-Bianchi P, 2015, CURR TREAT OPTIONS A, V2, P268
hcfmusp.relation.referenceIwamoto T, 2014, CANCER SCI, V105, P1472, DOI 10.1111/cas.12538
hcfmusp.relation.referenceIwamoto T, 2012, BIOL PHARM BULL, V35, P1487
hcfmusp.relation.referenceJakobsen A, 1997, J CLIN ONCOL, V15, P193
hcfmusp.relation.referenceJohansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
hcfmusp.relation.referenceKim BH, 2009, ONCOLOGY-BASEL, V76, P231, DOI 10.1159/000205263
hcfmusp.relation.referenceLi Q, 2014, GYNECOL ONCOL, V135, P90, DOI 10.1016/j.ygyno.2014.07.104
hcfmusp.relation.referenceMacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038
hcfmusp.relation.referenceMacy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021
hcfmusp.relation.referenceMadrigal-Burgaleta R, 2013, ALLERGY, V68, P853, DOI 10.1111/all.12105
hcfmusp.relation.referenceMakrilia Nektaria, 2010, Metal-Based Drugs, P207084, DOI 10.1155/2010/207084
hcfmusp.relation.referenceMarkman M, 1999, J CLIN ONCOL, V17, P1141
hcfmusp.relation.referenceMezzano V, 2014, BIODRUGS, V28, P133, DOI 10.1007/s40259-013-0066-x
hcfmusp.relation.referenceMoon DH, 2013, BRIT J CANCER, V109, P1072, DOI 10.1038/bjc.2013.389
hcfmusp.relation.referenceMori Y, 2010, ONCOLOGY-BASEL, V79, P136, DOI 10.1159/000320613
hcfmusp.relation.referenceNovak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039
hcfmusp.relation.referenceOcmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002
hcfmusp.relation.referenceOka T, 2013, J ALLERGY CLIN IMMUN, V132, P922, DOI 10.1016/j.jaci.2013.05.004
hcfmusp.relation.referenceParel M, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-1
hcfmusp.relation.referenceRubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x
hcfmusp.relation.referenceSancho-Serra MD, 2011, EUR J IMMUNOL, V41, P1004, DOI 10.1002/eji.201040810
hcfmusp.relation.referenceSantos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012
hcfmusp.relation.referenceSanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x
hcfmusp.relation.referenceSchwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010
hcfmusp.relation.referenceSeki K, 2011, INT J MED SCI, V8, P210
hcfmusp.relation.referenceShreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]
hcfmusp.relation.referenceSiu SWK, 2006, ANN ONCOL, V17, P259, DOI 10.1093/annonc/mdj042
hcfmusp.relation.referenceSong Woo-Jung, 2013, Asia Pac Allergy, V3, P266, DOI 10.5415/apallergy.2013.3.4.266
hcfmusp.relation.referenceSORENSEN BT, 1993, CANCER CHEMOTH PHARM, V31, P324, DOI 10.1007/BF00685679
hcfmusp.relation.referenceSturm EM, 2010, CYTOM PART B-CLIN CY, V78B, P308, DOI 10.1002/cyto.b.20526
hcfmusp.relation.referencevan de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014
hcfmusp.relation.referenceViardot-Helmer A, 2008, HAUTARZT, V59, P883, DOI 10.1007/s00105-008-1653-5
hcfmusp.relation.referenceWong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011
hcfmusp.relation.reference2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/J.ANAI.2010.08.002
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5aeba5b1-a416-4d64-931a-1d3750f77ad4
relation.isAuthorOfPublication17d6b151-3da6-4934-8fdb-cb6b6d0493a5
relation.isAuthorOfPublication.latestForDiscovery5aeba5b1-a416-4d64-931a-1d3750f77ad4
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_GIAVINA-BIANCHI_Basophil_Activation_Test_is_a_Relevant_Biomarker_of_2017.PDF
Tamanho:
1.04 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03